[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342773-105":59,"doc-detail-342773-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","deciphering-the-molecular-mechanisms-behind-drug-resistance-in-ovarian-cancer-to-unlock-efficient-treatment-options","Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options","","Ovarian cancer is a highly lethal gynecological malignancy often remaining undetected until advanced stages, which drives high morbidity and mortality. Clinical relapse frequently follows treatment, as drug resistance emerges and undermines the effectiveness of available therapies. This article reviews molecular mechanisms underlying resistance to carboplatin, paclitaxel, PARP inhibitors, and bevacizumab, including drug inactivation, target alterations, increased efflux, improved DNA damage repair, and reduced drug uptake. Mechanistic insight supports new biomarkers for predicting and tracking disease progression and for discovering therapeutic targets.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/deciphering-the-molecular-mechanisms-behind-drug-resistance-in-ovarian-cancer-to-unlock-efficient-treatment-options/342773/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/deciphering-the-molecular-mechanisms-behind-drug-resistance-in-ovarian-cancer-to-unlock-efficient-treatment-options/342773.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is drug resistance a major problem in ovarian cancer treatment?","Question",{"text":112,"@type":113},"Many patients relapse and ultimately succumb to ovarian cancer because resistance develops that limits the effectiveness of current oncological therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which therapies are discussed as drivers of resistance in this review?",{"text":117,"@type":113},"The review covers resistance mechanisms related to carboplatin, paclitaxel, PARP inhibitors, and bevacizumab.",{"name":119,"@type":110,"acceptedAnswer":120},"What main molecular categories of resistance mechanisms are analyzed?",{"text":121,"@type":113},"The article analyzes drug inactivation, drug target alterations, enhanced drug efflux pumps, increased DNA damage repair capacity, and reduced drug absorption or accumulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342773,1790272415,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","cells  \nReview  \nDeciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options  \nMariana Nunes 1,2, Carla Bartosch 3,4,5, Miguel Henriques Abreu 3,6, Alan Richardson 7, Raquel Almeida 1,8,9 and Sara Ricardo 1,9,10, *  \nCitation: Nunes, M.; Bartosch, C.; Abreu, M.H.; Richardson, A.; Almeida, R.; Ricardo, S. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options. Cells 2024, 13, 786. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells13090786](10.3390/cells13090786)  \nAcademic Editor: Jung-Hye Choi  \nReceived: 19 April 2024  \nAccepted: 1 May 2024  \nPublished: 4 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal; [mnunes@i3s.up.pt](mnunes@i3s.up.pt) (M.N.); [ralmeida@i3s.up.pt](ralmeida@i3s.up.pt) (R.A.)  \n2 Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal  \n3 Porto Comprehensive Cancer Center Raquel Seruca (PCCC), Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal; [carla.bartosch@ipoporto.min-saude.pt](carla.bartosch@ipoporto.min-saude.pt) (C.B.); [antonio.m.abreu@ipoporto.min-saude.pt](antonio.m.abreu@ipoporto.min-saude.pt) (M.H.A.)  \n4 Department of Pathology, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal  \n5 Cancer Biology & Epigenetics Group, Research Center of Portuguese Oncology Institute of  \nPorto (CI-IPO-Porto), Health Research Network (RISE@CI-IPO-Porto), Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal  \n6 Department of Medical Oncology, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal  \n7 The School of Pharmacy and Bioengineering, Guy Hilton Research Centre, Keele University, Thornburrow Drive, Stoke-on-Trent ST4 7QB, Staffordshire, UK; [a.richardson1@keele.ac.uk](a.richardson1@keele.ac.uk)  \n[8](8 Biology Department)[ Biology Department](8 Biology Department), [Faculty of Sciences](Faculty of Sciences), [University of Porto](University of Porto) ([FCUP](FCUP)), 4169-007 Porto, Portugal  \n9 Associate Laboratory i4HB, Institute for Health and Bioeconomy, University Institute of Health Sciences—CESPU, 4585-116 Gandra, Portugal  \n10 UCIBIO—Applied Molecular Biosciences Unit, Toxicologic Pathology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal  \n* Correspondence: [sricardo@i3s.up.pt](sricardo@i3s.up.pt)  \nAbstract: Ovarian cancer is a highly lethal form of gynecological cancer. This disease often goes undetected until advanced stages, resulting in high morbidity and mortality rates. Unfortunately, many patients experience relapse and succumb to the disease due to the emergence of drug resistance that significantly limits the effectiveness of currently available oncological treatments. Here, we discuss the molecular mechanisms responsible for resistance to carboplatin, paclitaxel, polyadenosine diphosphate ribose polymerase inhibitors, and bevacizumab in ovarian cancer. We present a detailed analysis of the most extensively investigated resistance mechanisms, including drug inactivation, drug target alterations, enhanced drug efflux pumps, increased DNA damage repair capacity, and reduced drug absorption/accumulation. The in-depth understanding of the molecular mechanisms associated with drug resistance is crucial to unveil new biomarkers capable of predicting and monitoring the kinetics during disease progression ","cbCailmWAYpYUJMJ","https://ap.wps.com/l/cbCailmWAYpYUJMJ","pdf",2961775,35,"English","# Introduction\n# Resistance Mechanisms Overview\n## Drug Inactivation and Target Alterations\n## Drug Efflux and DNA Damage Repair\n## Reduced Drug Absorption/Accumulation","[{\"question\":\"Why is drug resistance a major problem in ovarian cancer treatment?\",\"answer\":\"Many patients relapse and ultimately succumb to ovarian cancer because resistance develops that limits the effectiveness of current oncological therapies.\"},{\"question\":\"Which therapies are discussed as drivers of resistance in this review?\",\"answer\":\"The review covers resistance mechanisms related to carboplatin, paclitaxel, PARP inhibitors, and bevacizumab.\"},{\"question\":\"What main molecular categories of resistance mechanisms are analyzed?\",\"answer\":\"The article analyzes drug inactivation, drug target alterations, enhanced drug efflux pumps, increased DNA damage repair capacity, and reduced drug absorption or accumulation.\"}]","Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options | PDF",1790048184,88,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27d9800d241845500a758b5d3e13aa98.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb2758989f5e53e3cd0fa9f48c920e8f.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f53023f04024f7f10e4b544c1b4e5b00.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24d06fc924d2b4e85b692e92a593e414.webp",980,1385]